A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
Public ClinicalTrials.gov record NCT03523858. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis
Study identification
- NCT ID
- NCT03523858
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 927 participants
Conditions and interventions
Conditions
Interventions
- Ocrelizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 27, 2018
- Primary completion
- Oct 21, 2026
- Completion
- Oct 21, 2026
- Last update posted
- Apr 29, 2026
2018 – 2026
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MS Center of California | Laguna Hills | California | 92653 | — |
| SC3 Research Group, Inc | Pasadena | California | 91105 | — |
| University of California San Francisco | San Francisco | California | 94158 | — |
| Yale University | North Haven | Connecticut | 06473 | — |
| University of South Florida | Tampa | Florida | 33613 | — |
| University of Chicago | Chicago | Illinois | 60637-1470 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dragonfly Research, LLC | Wellesley | Massachusetts | 02481 | — |
| Wayne State University School of Medicine | Detroit | Michigan | 48210 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| The MS Center of Northeastern New York | Latham | New York | 12110 | — |
| University of Cincinnati | Cincinnati | Ohio | 45267 | — |
| Cleveland Clinic Mellen Center | Cleveland | Ohio | 44195 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Neurology Clinic PC | Cordova | Tennessee | 38018 | — |
| Central Texas Neurology Consultants | Round Rock | Texas | 78681 | — |
| Lone Star Neurology of San Antonio | San Antonio | Texas | 78258 | — |
| Swedish Multiple Sclerosis Center | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 106 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03523858, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03523858 live on ClinicalTrials.gov.